(Q43273886)

18 November 2017

title

Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma (English)

1 reference

18 November 2017

S-C Lee

1

1 reference

18 November 2017

S J Kim

2

1 reference

18 November 2017

D H Lee

3

1 reference

18 November 2017

W S Kim

4

1 reference

18 November 2017

C Suh

5

1 reference

18 November 2017

J-H Won

6

1 reference

18 November 2017

language of work or name

English

0 references

publication date

21 September 2009

1 reference

Bone Marrow Transplantation

18 November 2017

published in

1 reference

18 November 2017

volume

45

1 reference

18 November 2017

issue

4

1 reference

18 November 2017

page(s)

801-802

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2009.240

18 November 2017

exact match

0 references

cites work

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

inferred from DOI database lookup

7 January 2021

based on heuristic

Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.240

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2009.240

1 reference

Dimensions Publication ID

18 November 2017

1053225920

0 references

1 reference